Prostate Cancer

The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.

HRQOL results were evaluated in rural patients with bladder cancer and prostate cancer following ADT treatment and postoperative radiotherapy.

Pedro Barata, MD, discusses the expansion of radioligand therapies and the identification of novel targets beyond PSMA in prostate cancer.

Darolutamide generated lower treatment discontinuation rates and longer MFS vs enzalutamide or apalutamide in both Black and White patients with nmCRPC.

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Darolutamide plus ADT and docetaxel demonstrated efficacy benefits in men with mHSPC regardless of whether they were younger or older than 75 years of age.

Most patients with mCRPC included in a real-world study did not undergo HRR testing at the time of diagnosis.

Pivotal phase 3 trials are ongoing following data from a phase 1 study showing that adding mevrometostat to enzalutamide was safe and efficacious.

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.

Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.

The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.

Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.

A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.

G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.

Multidisciplinary treatment addresses all facets of patient health, resulting in personalized prostate cancer treatment plans that optimize outcomes.

The UK Medicines and Healthcare Products Regulatory Agency has approved the kit for the preparation of gallium-68 gozetotide injection.

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Jacob E. Berchuck, MD, shares next steps in research for a novel epigenomic liquid biopsy test for detecting PSMA in castration-resistant prostate cancer.

The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib, and acalabrutinib.

The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.